Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.
作者信息
Hofman Michael S
机构信息
Peter MacCallum Cancer Centre, Australia.
出版信息
J Nucl Med. 2021 Aug 12;62(12):1710-1. doi: 10.2967/jnumed.121.262890.
Abstract
摘要
相似文献
1
Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.为核医学带来愿景：通过诊疗一体化加速证据积累并改变范式。
J Nucl Med. 2021 Aug 12;62(12):1710-1. doi: 10.2967/jnumed.121.262890.
2
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.前列腺癌的放射性核素治疗：从单一治疗到联合PSMA诊疗一体化
J Nucl Med. 2021 Aug 12;62(12):1660-8. doi: 10.2967/jnumed.120.243295.
3
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.镥-177 前列腺特异性膜抗原（PSMA）放射性药物治疗：实用的细微差别和复杂性。
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):38-52. doi: 10.1038/s41391-019-0174-x. Epub 2019 Oct 8.
4
Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.将靶向前列腺特异性膜抗原（PSMA）的诊疗一体化技术纳入前列腺癌个性化治疗：多学科视角
Front Oncol. 2021 Jul 28;11:722277. doi: 10.3389/fonc.2021.722277. eCollection 2021.
5
Prostate-specific membrane antigen theranostics: therapy with lutetium-177.前列腺特异性膜抗原的治疗学应用：镥-177 治疗。
Curr Opin Urol. 2018 Mar;28(2):197-204. doi: 10.1097/MOU.0000000000000486.
6
Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.改变目标：前列腺特异性膜抗原靶向治疗前列腺癌的诊断与治疗一体化。
Semin Oncol Nurs. 2020 Aug;36(4):151052. doi: 10.1016/j.soncn.2020.151052. Epub 2020 Jul 13.
7
Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177.采用前列腺特异性膜抗原靶向镥-177 的治疗诊断一体化策略。
Pract Radiat Oncol. 2022 Jul-Aug;12(4):300-304. doi: 10.1016/j.prro.2022.01.008. Epub 2022 May 14.
8
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.先进前列腺癌的治疗策略：当前的适应证和未来的发展。
Eur Urol Oncol. 2019 Mar;2(2):152-162. doi: 10.1016/j.euo.2019.01.001. Epub 2019 Jan 31.
9
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).EANM 程序指南：镥[177Lu]标记的 PSMA 配体（Lu-PSMA-RLT）放射性核素治疗。
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.
10
The application of theranostics in different stages of prostate cancer.治疗诊断学在前列腺癌不同阶段的应用。
Future Oncol. 2021 Sep;17(27):3637-3644. doi: 10.2217/fon-2020-1209. Epub 2021 Jul 6.
引用本文的文献
1
Radiolabeled PSMA Inhibitors.放射性标记的前列腺特异性膜抗原（PSMA）抑制剂
Cancers (Basel). 2021 Dec 13;13(24):6255. doi: 10.3390/cancers13246255.
本文引用的文献
1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
2
UpFrontPSMA: a randomized phase 2 study of sequential Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).UpFrontPSMA：一项转移性去势敏感前列腺癌中先后接受 Lu-PSMA-617 和多西他赛与多西他赛治疗的随机 2 期研究（临床试验方案）。
BJU Int. 2021 Sep;128(3):331-342. doi: 10.1111/bju.15384. Epub 2021 Apr 21.
3
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of Lu-PSMA-617 Prior to Prostatectomy.LuTectomy 临床试验方案：Lu-PSMA-617 在前列腺切除术之前的剂量学、安全性和潜在获益的单臂研究。
Eur Urol Focus. 2021 Mar;7(2):234-237. doi: 10.1016/j.euf.2020.09.021. Epub 2020 Nov 7.
4
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.Lu-PSMA-617 治疗剂在转移性去势抵抗性前列腺癌中的扩大 50 例单中心前瞻性 II 期试验的长期随访和再治疗结果。
J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15.
5
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.卡巴他赛对比阿比特龙或恩杂鲁胺用于转移性前列腺癌。
N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30.
6
Nuclear Medicine and Wall Street: An Evolving Relationship.核医学与华尔街：一种演进中的关系。
J Nucl Med. 2019 Sep;60(Suppl 2):20S-24S. doi: 10.2967/jnumed.118.220798.
7
Dosimetry of Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.镥-PSMA-617 治疗转移性去势抵抗性前列腺癌的剂量学研究：治疗前影像学检查与全身肿瘤剂量学与治疗结果的相关性。
J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5.
8
[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.[镥]-PSMA-617 放射性核素治疗转移性去势抵抗性前列腺癌患者（LuPSMA 试验）：一项单中心、单臂、2 期研究。
Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.
9
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.治疗诊断用前列腺特异性膜抗原（PSMA）配体PSMA-617在PET/CT诊断前列腺癌中的应用：人体生物分布、辐射剂量测定及肿瘤病变的首次评估
J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20.
10
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.68Ga- 和 177Lu-标记的 PSMA I&T：PSMA 靶向治疗概念的优化及首例概念验证人体研究。
J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18.
Zotero 插件